Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 3/20 | 0.71 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.71 |
| ▸ | F2 | P00734 | 2/20 | 0.71 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.71 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.71 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.71 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | PLG | P00747 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | PLAT | P00750 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841312 | 0.91 | ITGB3 (0.66) | PRSS1ST14F2PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL1438132 | 0.87 | PRSS1 (0.65) | PRSS1ST14F2PRSS2PRSS3 | |
| SCHEMBL13094273 | 0.87 | ITGB3 (0.66) | PRSS1ST14F2PRSS2PRSS3 | |
| SCHEMBL1189501 | 0.87 | F2 (0.65) | PRSS1ST14F2PRSS2PRSS3 | |
| SCHEMBL13094271 | 0.87 | ITGB3 (0.66) | PRSS1ST14F2PRSS2PRSS3 | |
| SCHEMBL8502841 | 0.85 | ITGB3 (0.68) | PRSS1ST14F2PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL30314839 | 0.85 | ITGB3 (0.64) | PRSS1ST14F2PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL30701848 | 0.85 | ITGB3 (0.64) | PRSS1ST14F2PRSS2PRSS3 | |
| SCHEMBL3093114 | 0.85 | ITGB3 (0.64) | PRSS1ST14F2PRSS2PRSS3 | |
| SCHEMBL3081459 | 0.85 | ITGB3 (0.64) | PRSS1ST14F2PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | PRSS1 2062/4885ST14 3028/4885F2 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.